Akèy › Kansè pwostat › Washington › Seattle
Etid klinik pou Kansè pwostat nan Seattle, WA
42 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- ak 1 plis
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Ap rekriteFaz 1
- Swedish Medical Center, Seattle
Precision-Based Genomics in Prostate Cancer
Ap rekriteEtid obsèvasyon
- University of Washington, Seattle
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Fred Hutchinson Cancer Research Center, Seattle
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Ap rekriteFaz 2/3
- Fred Hutchinson Cancer Research Center, Seattle
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Ap rekriteFaz 3
- Swedish Medical Center, Seattle
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Ap rekriteFaz 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Ap rekriteFaz 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- VA Puget Sound Health Care System ( Site 0054), Seattle
- Fred Hutchinson Cancer Center ( Site 0060), Seattle
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
Ap rekriteEtid obsèvasyon
- University of Washington Medical Center, Seattle
The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Ap rekriteFaz 2
- University of Washington, Seattle
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- Fred Hutchinson Cancer Center, Seattle
- FHCC at Northwest Hospital, Seattle
- University of Washington Medical Center - Montlake, Seattle
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Ap rekriteFaz 1
- Investigational Site Number: 400, Seattle
Prostate Active Surveillance Study
Ap rekriteEtid obsèvasyon
- Veterans Affairs Puget Sound Health Care System, Seattle
- University of Washington, Seattle
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
Ap rekriteFaz 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
Ap rekriteFaz 2
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Ap rekriteFaz 2
- University of Washington Medical Center, Seattle
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Ap rekriteFaz 2
- Fred Hutchinson Cancer Center, Seattle
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Ap rekriteFaz 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- ak 4 plis
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ap rekriteFaz 2
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Ap rekriteFaz 2
- Fred Hutchinson Cancer Center, Seattle
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Ap rekriteEtid obsèvasyon
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Ap rekriteFaz 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial
Ap rekrite
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- ak 4 plis
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Ap rekriteFaz 1
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
Ap rekriteFaz 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Ap rekriteFaz 2
- VA Puget Sound Health Care System, Seattle
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Fred Hutchinson Cancer Center, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Ap rekriteFaz 2
- Swedish Medical Center-Ballard Campus, Seattle
- FHCC South Lake Union, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
- ak 4 plis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Seattle
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- FHCC South Lake Union, Seattle
- FHCC at Northwest Hospital, Seattle
- University of Washington Medical Center - Montlake, Seattle
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Washington, DC38 etid
- Dallas, TX36 etid
Lòt etid nan Seattle
- Kansè Poumon ki pa ti selil53 etid
- Kansè (tout kalite)49 etid
- Leksemi mieloïd egi40 etid
- Kansè nan tete39 etid
- Kansè Metastatik39 etid
- Kansè kolorektal34 etid
- Kansè poumon33 etid
- Kansè ovè30 etid
- Myelom Miltip22 etid
- Sendwòm myelodisplastik21 etid
- Leksemi limfoblastik egi21 etid
- Kansè vejik21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.